Following the wildly successful acquisition and integration of Modern Everyday, Inc., LiveDeal Inc. (NASDAQ – LIVE - $3.26 – Spec Buy) recently announced that it has initiated a new acquisition strategy designed to leverage the success of the August 2014 purchase and its current restaurant deal segment. 

One of the untold stories regarding the recent transformation of PharmaCyte Biotech (OTCQB – PMCB - $0.1649 – Spec Buy) is that much of it is owed to the new leadership team.  In the span of just over a year, Chief Executive Officer Kenneth L. Waggoner has significantly upgraded the quality of the Company’s leadership team, particularly with respect to the clinical research and execution side, which is a veritable “Who’s Who” in the global scientific community.

One factor that could enable LiveDeal to obtain and retain online customer loyalty is its timed “Live” offering, which was associated with each deal we reviewed. Price conscious shoppers tend to gravitate to the lowest prices. However, if the consumer believes that these prices are lower now and will be lower going forward because of the deal opportunities on the website, they will return again and again to purchase products.  This cycle could lead to substantial business and revenue gains this year.

In contrast, ModernEveryday Inc., a LiveDeal subsidiary, is on track to generating significant gross profit margins later this year as it begins to produce some of its most popular goods, thereby giving it substantial pricing power. This subsidiary’s operating performance success in 2015 should prompt LiveDeal to outshine the valuation afforded companies like Overstock, whose fortunes are also tied to the household and housewares segments, and trades over 30x this year’s EPS estimate. 

A major scientific journal recently published a study led by one of PMCB’s Diabetes Consortium members. The animal study showed that a new cell line designed by the study’s authors have developed a method of reversing Type 1 diabetes.  The key is that in order for the cell line to reverse Type 1 diabetes in humans, the cells must be encapsulated in a cocoon, as in PMCB’s Cell-in-a-Box technology.

It is no surprise that PharmaCyte Biotech’s (OTCQB – PMCB - $0.1226 – Spec Buy) treatment for pancreatic cancer retains such a high profile in the oncology community. After all, the Company is about to embark on another mid-stage clinical trial to treat pancreatic cancer using its innovative flagship technology.

Interestingly, online pioneer Priceline.com is approaching its 52-week high as it nears the one-year anniversary of the Opentable acquisition for $2.6 billion. An online reservation service with tens of thousands of restaurants in stable, Opentable is the leader in its space which why its acquisition carried such a high valuation. As LiveDeal grows its own stable of restaurant clients offering live deals, it is clear that a future value for the company could be substantial.

Clearly this enhanced approach by the FDA has had a great impact on biotech stocks and bodes well for companies like PharmaCyte Biotech, should they be entered into any of the accelerated review tracks above.   In any event, the FDA’s current accommodative stance should continue to serve as a biotech stock driver going forward.

Judging by its success in adding new restaurant deals, the Company's consumer base and its restaurant partners have been very receptive to its real-time deal engine and instant offers, which restaurant partners using the platform can turn on and off as desired.  Going forward, it seems that the Company will continue to directly target restaurant owners and operators and increase the “daily time on site” per visitor, which should translate into additional revenue.

Since the Company’s Cell-in-a-Box(R) live cell encapsulation technology has such broad potential applications, it could emerge as a universal therapy for the treatment of multiple forms of cancer and diabetes and compete with a number of existing, billion dollar products, potentially making PharmaCyte Biotech the prototypical acquisition target.